Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peglamda Phase 1a/1b in Healthy Volunteers and Chronic Hepatitis C
NCT02063607Phase 1Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peginterferon lambda-1 in hepatitis C (HCV) (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoints: Area Under the Concentration-Time Curve (AUC 0-336) at 336 hours and Rapid Virological Response at 4 weeks. Started Dec 2013; status: completed.
02
Drugs
peginterferon lambda-1
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02063607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063607.